Abstract
<p class="Abstract">The objective of the present study was to investigate the anti-cancer effects of eriodictyol in human hepatocellular carcinoma cells (Hep-G2) and normal liver hepatocyte cell line (AML12) along with evaluating its mode of action. Sulforhodamine B assay was used to evaluate the cytotoxic effect of the compound while as fluorescence microscopy was involved to demonstrate the effect of eriodictyol on cellular apoptosis. Flow cytometry was used to investigate the effect of eriodictyol on cell cycle while Western blot analysis revealed the effect on apoptosis-related protein expressions. Results indicate that eriodictyol-induced selective and concentration-dependent cytotoxic effect on Hep-G2 cancer cells while AML12 normal liver cells were very less susceptible to its effect. Eriodictyol-induced apoptosis related morphological changes including chromatin condensation and nuclear fragmentation. It also induced G2/M cell cycle arrest in these cells. Eriodictyol led to up-regulation of Bax and PARP and down-regulation of Bcl-2 protein.</p><p><strong>Video Clip</strong></p><a href="https://youtube.com/v/MJwBotwrgWM">Flow cytometry assay</a>: 35 sec<p> </p>
Highlights
Hepatocellular cancer was the second most common cause of death during 2009-2010 throughout the world
Hep-G2 human liver cancer cell line was purchased from the Shanghai Institute of Cell Resource Center of Life Science (China) while as AML12 normal liver hepatocyte cell line was procured from American Type Culture Collection (USA)
The apoptosis inducing effect of eriodictyol was further assessed by DAPI staining using fluorescence microscopy
Summary
Hepatocellular cancer was the second most common cause of death during 2009-2010 throughout the world. Hepatocellular cancer has a 5-year natural mortality rate of more than 90%, and it affects more than 500,000 people in the world per year, more than 50% of whom are in China (Amin et al, 2011). The treatment options for hepatocellular cancer include chemotherapy, surgical resection and radiotherapy. One of the most effective treatment options for hepatocarcinoma includes liver transplantation. Multidrug resistance and high risk of tumor recurrence further complicates the treatment regimens for hepatocellular cancer (Amin et al, 2011; Tabone and Pellicano, 2006). There is an urgent need for more effective, novel and less toxic anticancer agents against liver cancer including natural products and their synthetic or semisynthetic derivatives
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
